Orphan and Fast Track Phanes has FDA orphan drug and Fast Track designations for spevatamig and peluntamig, signaling strong regulatory incentives and potential for expedited development, which can be leveraged in partnership discussions with sponsors seeking accelerated oncology programs.

Pipeline Collaboration Lead asset spevatamig targets multiple cancer indications and is being studied in combination with chemotherapy and pembrolizumab, presenting multiple co-development and trial collaboration opportunities with pharma companies looking to expand immuno-oncology portfolios.

Clinical Momentum Phase 2 progress with completed enrollment in frontline metastatic PDAC trials and positive early results showcased at ASCO and AACR provide a compelling entry point for discussions around licensing, co-development, or strategic investment.

Global Dosing Footprint 180 patients dosed with spevatamig globally in monotherapy and combination settings indicate existing international execution capabilities, offering scalability assurance to potential partners seeking global trials and manufacturing alignment.

Financial and Strategic Fit Moderate funding and mid-market revenue positioning, combined with a focused oncology portfolio and strategic collaborations (e.g., Merck for pembrolizumab combination), suggest opportunities for value-adding partnerships, co-investments, or in-licensing discussions to accelerate pipeline progression.